Lincoln Pharmaceuticals' Credit Ratings Reaffirmed: CRISIL A/Stable and CRISIL A1
Lincoln Pharmaceuticals Limited's long-term bank facilities are reaffirmed at CRISIL A/Stable and short-term facilities at CRISIL A1 by CRISIL on January 9, 2026. The ratings are supported by promoter experience, market position, and financial health. Revenue grew 14% to ₹623 crore in FY25.
Credit rating updates are important for a company's borrowing costs and investor confidence. While positive, it is not a direct financial result or a major strategic announcement, hence the medium impact.
The reaffirmation of credit ratings at a stable and positive level (CRISIL A/Stable and CRISIL A1) indicates a strong financial health and market position for the company, which is a positive development.
Lincoln Pharmaceuticals Limited (LPL) has received a confirmation of its credit rating from CRISIL Limited. The long-term bank facilities have been reaffirmed at CRISIL A/Stable, and the short-term bank facilities have been reaffirmed at CRISIL A1. These ratings were confirmed by CRISIL on January 9, 2026.
The ratings reflect the promoters' extensive experience in the pharmaceutical industry, the group's established market position, and a healthy financial risk profile. Strengths include a widespread geographical reach, a diverse clientele and product base, and strong promoter experience of over three decades. LPL derives 60-65% of its revenue through exports and has over 1,700 registered products across more than 15 therapeutic segments. Revenue increased at a CAGR of 10% in the five fiscals through 2024, growing 14% year-on-year to ₹623 crore in fiscal 2025. The group is expected to grow 7-8% annually over the medium term, with plans for new product launches and market expansion, including entry into the European market.
The group's financial risk profile is robust, with consolidated net worth at ₹671 crore and nil debt as of March 31, 2025. Interest coverage stood at a comfortable 91.01 times in fiscal 2025. However, the ratings are partially offset by working capital-intensive operations, with gross current assets expected to be sizeable due to receivables and inventory. The group also faces exposure to regulatory risks and intense competition in the pharmaceutical sector. Additionally, the extension of sizeable loans and advances to affiliates and individuals (amounting to ₹141 crore as of March 31, 2025) is a monitorable factor.
CRISIL believes the Lincoln group will continue to benefit from its established market presence and healthy financial risk profile. The outlook is stable, with upward factors including a 20% CAGR revenue increase and improved geographical diversification, while downward factors include operating profitability below 13% or a stretched working capital cycle.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under credit ratings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.